Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965767 | 0.93 | HCRTR1 (0.48) | HCRTR1HCRTR2GAATSHR | |
| SCHEMBL1967471 | 0.92 | CHRM5 (0.42) | HCRTR1HCRTR2KDM4ENPC1 | |
| SCHEMBL1967329 | 0.91 | HCRTR1 (0.50) | HCRTR1HCRTR2NPC1 | |
| SCHEMBL1969317 | 0.90 | HCRTR1 (0.43) | HCRTR1HCRTR2GAAOXTRAVPR1A | |
| SCHEMBL2406960 | 0.89 | HCRTR1 (0.43) | HCRTR1HCRTR2KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL2407884 | 0.87 | TP53 (0.42) | HCRTR1HCRTR2SMN1; SMN2GAATP53 | |
| SCHEMBL1969287 | 0.85 | KDM4E (0.41) | HCRTR1HCRTR2KDM4ESMN1; SMN2NPSR1 | |
| SCHEMBL1971609 | 0.85 | HCRTR1 (0.51) | HCRTR1HCRTR2KDM4ESMN1; SMN2TP53 | |
| SCHEMBL1970040 | 0.84 | HCRTR1 (0.38) | HCRTR1HCRTR2KDM4EGAATSHR | |
| SCHEMBL1971975 | 0.84 | HCRTR1 (0.50) | HCRTR1HCRTR2KDM4ESMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR1 2/4885HCRTR2 1/4885KDM4E 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.